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Historically, up to 30% of patients were unable to collect adequate numbers of peripheral blood stem cells
(PBSCs) for autologous stem cell transplantation (ASCT). Plerixafor in combination with granulocyte colony-
stimulating factor (G-CSF) has shown superior results in mobilizing peripheral blood (PB) CD34þ cells in
comparison to G-CSF alone, but its high cost limits general use. We developed and evaluated risk-adapted
algorithms for optimal utilization of plerixafor. In plerixafor-1, PBSC mobilization was commenced with
G-CSF alone, and if PB CD34 on day 4 or day 5 was <10/mL, plerixafor was administered in the evening, and
apheresis commenced the next day. In addition, if on any day, the daily yield was <0.5  106 CD34/kg,
plerixafor was added. Subsequently, the algorithm was revised (plerixafor-2) with lower thresholds. If day-4
PB CD34 <10/mL for single or <20/mL for multiple transplantations, or day-1 yield was <1.5  106 CD34/kg, or
any subsequent daily yield was <0.5  106 CD34/kg, plerixafor was added. Three time periods were analyzed
for results and associated costs: January to December 2008 (baseline cohort; 319 mobilization attempts in 278
patients); February to November 2009 (plerixafor-1; 221 mobilization attempts in 216 patients); and
December 2009 to June 2010 (plerixafor-2; 100 mobilization attempts in 98 patients). Plerixafor-2 shows
a signiﬁcant improvement in PB CD34 collection, increased number of patients reaching minimum and
optimal goals, fewer days of apheresis, and fewer days of mobilization/collection, albeit at increased costs. In
conclusion, although the earlier identiﬁcation of ineffective PBSC mobilization and initiation of plerixafor
(plerixafor-2) increases the per-patient costs of PBSC mobilization, failure rates, days of apheresis, and total
days of mobilization/collection are lower.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy and autologous stem cell trans-
plantation (ASCT) has become a standard procedure formany
patients with non-Hodgkin lymphoma (NHL), Hodgkin
lymphoma, and plasma cell disorders (including multiple
myeloma, POEMS syndrome and immunoglobulin light chain
amyloidosis). A requirement to undergo ASCT is adequate
mobilization and collection of hematopoietic progenitor cells
either from the bone marrow (BM) or, preferably, from the
peripheral blood (PB). The most common strategy for
obtaining peripheral blood stem cells (PBSCs) is with gran-
ulocyte colony-stimulating factor (G-CSF) alone or in combi-
nationwith chemotherapy. Historically, using thesemethods,
up to 30% of patients fail to collect a minimum number of
CD34 cells to support ASCT [1,2]. Pusic et al. [2], in a retro-
spective review of 1,834 patients undergoing stem cell
mobilization for ASCT, demonstrated that 18.6% and 18.8% ofdgment on page 93.
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12.08.010patients failed to collect 2  106 CD34/kg with G-CSF alone
and G-CSF and chemotherapy, respectively. In addition, only
28.7%collected>5106CD34/kg,whichwasconsidered tobe
the optimal cell dose. Similarly, Gertz et al. [1] demonstrated
a failure rate of 22% in patients undergoing PBSCmobilization
formultiplemyeloma, NHL, andHodgkin lymphoma. Of 1,775
patients undergoing stem cell mobilization, 10% had poor
collections deﬁned at <2  106 CD34/kg, and 12% had
no collections attempted as their PB CD34þ cells remained
<10/mL. Likewise, only 53% of patients collected the optimal
cell dose of >5  106 CD34/kg. In the 47% of patients who
collected less than the optimal cell dose, increased resource
consumption was demonstrated including increased use of
growth factors, antibiotics, remobilization attempts, trans-
fusion support, increased apheresis procedures, and more
frequent hospitalizations. Other studies have shown that
higher CD34 cell doses result in faster engraftment, shorter
hospitalizations, less anti-infective agents, and fewer red cell
and platelet transfusions, and some studies also showed an
improveddisease-free andoverall survival compared to lower
CD34 cell doses [3-8].
Plerixafor is a partial antagonist of the a-chemokine
receptor CXCR4. It reversibly inhibits SDF-1 binding toTransplantation.
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SDF-1 ligand and CXCR4 is important for homing and
retention in the BM. When this interaction is interrupted,
there is rapid egress of the stem cells from the BM into the
PB. Recent phase III studies have shown that plerixafor in
combination with G-CSF results in increased mobilization of
CD34þ cells compared to G-CSF alone [11,12]. In addition,
plerixafor þ G-CSF have also been shown to successfully
mobilize the majority of patients who previously failed to
mobilize with either growth factor alone or in combination
with chemotherapy [13,14].
Plerixafor given in combinationwith G-CSF received Food
and Drug Administration (FDA) approval in December 2008
for autologous PBSC mobilization in patients with multiple
myeloma and NHL [15]. However, its high cost has restricted
its universal use in autologous stem cell mobilization. It was
unclear if it should be reserved as a remobilization strategy
or for selected patients known to be at high risk for mobili-
zation failure. Therefore, we developed a risk-adapted algo-
rithm for patients undergoing upfront autologous PBSC
mobilization with G-CSF alone. In this algorithm, patients
demonstrating ineffective stem cell mobilization character-
ized by a low PB CD34 cell count during mobilization or by
apheresis yield would initiate plerixafor. We hypothesized
that targeting the patients who were mobilizing poorly
would result in a cost savings compared to universal use of
plerixafor in all patients undergoing upfront mobilization
and be preferable to reserving plerixafor as a remobilization
strategy.PATIENTS AND METHODS
All patients provided written informed consent for use of their medical
records. Approval from the Mayo Clinic Institutional Review Board was
obtained in accordance with federal regulations and the Declaration of
Helsinki. All patients undergoing ﬁrst-time mobilization for ASCT with
either growth factor alone or chemotherapy were included. Patients who
participated in the phase II and phase III clinical trials with upfront
plerixaforþG-CSF were excluded from the analysis. Patients who previously
had failed to mobilize prior to 2008 were also excluded.
The endpoints analyzed were total CD34þ cells collected during ﬁrst-
time mobilization and remobilization, percentage of patients achieving 2
and 4  106 CD34/kg, days of apheresis, days of mobilization and collec-
tion, plerixafor use including percentage of patients who required plerixafor
and number of days of plerixafor, and total costs per patient. For the cost
analysis, the costs included the acquisition cost of drugs (G-CSF, granulocyte
macrophage colony-stimulating factor, plerixafor, and cyclophosphamide),
daily apheresis costs, and cryopreservation costs (Table 1). Supportive care
costs including transfusions, antimicrobials, hospitalization, nursing costs,
and the patient’s personal costs were not included. Remobilization costs
were added to the ﬁrst mobilization procedure for the patient’s total costs.
From January 2008 to June 2010, we identiﬁed 592 patients from our
prospectively maintained transplantation database who were undergoing
their ﬁrst attempt at PBSC mobilization. These patients were divided into 3
groups: those mobilized during 2008 served as the “baseline” cohort beforeTable 1
Cost Analysis Assumptions
Costs Included Cost Costs Not Included
G-CSF $500 per day Chemotherapy if used as salvage
therapy
GM-CSF $500 per day Transfusions
Plerixafor $6,250 per day Antimicrobials
Apheresis $1,500 per day Hospital stay
Cryopreservation $1,500 per
apheresis
Patients’ personal costs of food
and lodging
Cyclophosphamide $500 per dose Stafﬁng costseweekend,
overtime
G-CSF indicates granulocyte colony-stimulating factor; GM-CSF, gran-
ulocyte macrophage colony-forming unit.the FDA approval of plerixafor, those mobilized using the initial risk-adapted
algorithm from February to November 2009 were designated “plerixafor-1,”
and those using the revised risk-adapted algorithm used from December
2009 to June 2010 were designated “plerixafor-2.” Minimal CD34 collected
was deﬁned as 2  106 CD34/kg, and optimal CD34 collected was deﬁned
as 4  106 CD34/kg.
Apheresis
Several Fenwal Amicus, version 2.5 (Fenwal Inc., Lake Zurich, IL)
apheresis systems were used. All PBSC collections had an endpoint of 5-hour
processing time. Anticoagulant was ACD-A (Baxter Healthcare Corp.,
Deerﬁeld, IL) or a mixture of ACD-A, normal saline, and heparin [16].
If the patient’s preprocedure peripheralWBC count was>35109/L, the
maximum blood ﬂow rate was 65 mL/min. This was done, as previous
studies demonstrated an adverse effect of a high WBC count on CD34þ cell
yields [17,18]. For patients with a WBC count of >35  109/L, additional
settings were as follows: cycle volume 1,000mL, citrate infusion rate 2.5 mg/
kg/min, and anticoagulant ratio 13:1. The plasma ﬂush setting was 8 mL. If
the patient’s preprocedure peripheral WBC count was 35  109/L, the
following settings were used: cycle volume 1,400 mL, maximum blood ﬂow
rate 90 mL/min, citrate infusion rate 2.50 mg/kg/min, and anticoagulant
ratio 12:1. The plasma ﬂush setting was 8 mL.
The mononuclear cell offset was 1.5 mL, and the RBC offset was 5.0 mL
regardless of the patient’s preprocedure WBC count. If the patient’s pre-
procedure preplatelet count was 300  109/L, then the RBC offset started
at 6.0 mL. For all collections, the operator observed the ﬁrst cycle mono-
nuclear cell transfer to determine if the RBCs passed completely through the
right cassette. If the RBCs did not reach the top of the cassette, the operator
increased the RBC offsets to the next level for each succeeding cycle until the
RBCs reached the top of the right cassette [19].
Baseline Cohort Algorithm
PBSCmobilization consisted of G-CSF given subcutaneously (10 mg/kg/d)
for 4 days with a PB CD34 count measured on day 4. If day 4 PB CD34 count
was 10/mL, apheresis was commenced the following day. If day 4 PB CD34
was <10/mL, G-CSF was continued, and the PB CD34 count was measured
daily; once the PB CD34 count was 10/mL, apheresis was started the
following day. At the transplantation physician’s discretion, G-CSF could be
increased to 16 mg/kg twice a day. For patients who received chemotherapy
in combination with G-CSF, G-CSF was commenced at 5 mg/kg/d, starting
day þ1 postchemotherapy. When the WBC count reached >1  109/L daily,
PB CD34 measurements were commenced. When CD34 reached 10/mL,
apheresis commenced. Apheresis was continued daily with G-CSF until
either goal was achieved or until the daily yield was <0.5  106 CD34/kg. If
either total apheresis was <2  106 CD34/kg or if PB CD34 remained <10/mL
after multiple days, then the mobilization attempt was stopped and
considered a mobilization failure.
Plerixafor-1 Cohort Algorithm
PBSCmobilization consisted of G-CSF given subcutaneously (10 mg/kg/d)
for 4 days with a PB CD34 count measured on day 4. If day 4 PB CD34 count
was 10/mL, apheresis was commenced the following day. If day 4 PB CD34
was <10/mL, G-CSF was continued, and the PB CD34 count was measured on
day 5. If the PB CD34 count was 10/mL, apheresis was started the following
day. If day 5 PB CD34 was <10/mL, then plerixafor was added (0.24 mg/kg/d)
in the evening of day 5, and apheresis was initiated the following day. In
addition, if the apheresis yield on any day was <0.5  106 CD34/kg/d,
plerixafor was added, and apheresis was continued (Figure 1A). For patients
who received chemotherapy in combination with G-CSF, G-CSF was
commenced at 5 mg/kg/d, starting day þ1 postchemotherapy. When the
WBC count was>1109/L, daily PB CD34measurements were commenced.
When CD34 reached 10/mL, apheresis commenced. In chemotherapy
mobilization, the addition of plerixafor was at the discretion of the treating
transplantation physician. Apheresis was continued daily with daily
administration of G-CSF (mornings) and plerixafor (evenings) until either
the apheresis goal was achieved or the daily yield was <0.5  106 CD34/kg
on 2 consecutive days. If the total apheresis yield was <2  106 CD34/kg,
then collection was stopped, and the mobilization attempt was considered
a failure.
Plerixafor-2 Cohort Algorithm
As before, PBSC mobilization consisted of G-CSF given subcutaneously
(10 mg/kg/d) for 4 days with a PB CD34 count checked on day 4. If day 4
PB CD34 count was 10/mL, or 20/mL if collecting for more than
1 transplantation, then apheresis was commenced the following day. If
day 4 PB CD34 was <10/mL, or <20/mL if collecting for more than
1 transplantation, then plerixafor was added (0.24 mg/kg/d) on the
evening of day 4, and apheresis was initiated the following day. In
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Figure 1. (A) and (B) Flow diagrams of plerixafor risk-adapted algorithms.
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subsequent daily yield was <0.5  106 CD34/kg/d, plerixafor was added,
and apheresis was continued (Figure 1B). For patients who received
chemotherapy in combination with G-CSF, G-CSF was commenced at 5 mg/
kg/d, starting day þ1 postchemotherapy. When the WBC count was >1 
109/L, daily PB CD34 measurements were commenced. When CD34
reached 10/mL, apheresis commenced. Addition of plerixafor occurred if
PB CD34 failed to reach 10/mL after 3 days that the WBC count was >1 
109/L or at the discretion of the treating transplantation physician.
Apheresis was continued daily with daily administration of G-CSF
(mornings) and plerixafor (evenings) until either the apheresis goal was
achieved or the daily yield was <0.5  106 CD34/kg on 2 consecutive
days. If the total apheresis yield was <2  106 CD34/kg, then collection
was stopped, and the mobilization attempt was considered a failure.
Statistics
The chi-square and Fisher exact tests were used to compare differ-
ences between nominal variables, and the ManneWhitney U test or
KruskaleWallis test were used for continuous variables. KaplaneMeier
analysis was performed to determine the median time to achievement
of speciﬁc CD34 targets, and the curves were compared using the log-rank
test.Table 2
Baseline Patient Characteristics
Baseline P
Patients (n ¼ 592) 278 2
Mobilization attempts 319 2
Disease
Plasma cell disorder 158 (57%) 1
NHL/Hodgkin lymphoma 120 (43%)
Age: median (range) 59 (24-76)
Gender: male/female 176/102 1
Chemotherapy mobilization 28 (10%)
NHL indicates non-Hodgkin lymphoma.RESULTS
Patient Characteristics
Overall, 592 patients were included; 278 in the baseline
group, 216 in the plerixafor-1 group, and 98 in the plerixafor-
2 group. Baseline patient characteristics are outlined by
group in Table 2 and were similar across groups. A higher
proportion of patients in each group had plasma cell disor-
ders. More patients in the baseline cohort underwent
chemotherapymobilization (10% vs 1% vs 2% for the baseline,
plerixafor-1, and plerixafor-2 groups, respectively).Apheresis
The collection process, including the length of apheresis,
ﬂow rates, apheresis devices, and vascular access did not
change during these time periods. The blood volume pro-
cessed per apheresis session in all 3 cohorts was similar. The
mean blood volumes processed in the baseline cohort,
plerixafor-1, and plerixafor-2 groups were 16.94 L, 17.05 L,lerixafor-1 Plerixafor-2 P Value
16 98 -
21 100 -
40 (65%) 66 (67%)
76 (35%) 32 (32%) NS
58 (22-76) 57 (21-71) NS
28/88 61/37 NS
3 (1%) 2 (2%) <.001
Figure 2. (A) Kaplan-Meier cumulative incidence plot of percentage of
patients achieving CD34 stem cell yield of 2  106 CD34/kg based on number
of days. (B) Kaplan-Meier cumulative incidence plot of percentage of patients
achieving CD34 stem cell yield of 4  106 CD34/kg based on number of days.
Table 3
First Mobilization Results
Patient Cohorts Baseline (n ¼ 278) Plerixafor-1 (n ¼ 216) Plerixafor-2 (n ¼ 98) P Value
CD34 collected (106/kg)
Median 5.6 6.1 7.8
Range 0-26 0.1-28 1.6-29.3 <.001
Mean 5.9 7 8.3
4  106/kg (%) 201 (72%) 181 (84%) 91 (93%) <.001
2  106/kg (%) 226 (81%) 206 (95%) 97 (99%) <.001
Day-1 apheresis yield 2.3 (0-26) 2.4 (0.03-28) 3.7 (0.5-29) <.001
Mobilization failures 52 (19%) 10 (5%) 1 (1%) <.001
Remobilizations 39 (14%) 5 1 <.001
Plerixafor use 0 82 (38%) 57 (58%) <.001
Indication for plerixafor use
Day-4 CD34 <10 - 9 34
Day-4 CD34 <20 - - 10
Day-5 CD34 <10 - 33 -
Day-1 apheresis yield <1.5  106/kg - - 10
Any apheresis yield <0.5  106/kg - 40 3
Days of plerixafor
Median - 3 2 .007
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volumes processed in the baseline cohort, plerixafor-1, and
plerixafor-2 groups were 15.99 L, 16.01 L, and 16.10 L,
respectively (P ¼ NS).
First Mobilization Results
The median CD34 collected during the ﬁrst mobilization
attempt was 5.6  106 CD34/kg in the baseline group
compared to 6.1 in the plerixafor-1 group and 7.8 in the
plerixafor-2 group (Table 3). Signiﬁcantly more patients were
able to achieve an optimal goal of PBSC in the plerixafor-2
group compared to the plerixafor-1 and baseline groups. In
the baseline cohort, 72% and 81% of patients were able to
collect goals of 4  106 CD34/kg and 2  106 CD34/kg,
respectively. In the plerixafor-1 group, 84% collected 4 
106 CD34/kg, and 95% collected 2  106 CD34/kg. In the
plerixafor-2 group, 93% collected 4  106 CD34/kg and 99%
collected2106 CD34/kg (P< .001). Themedian estimated
time to achieving the goal of 4  106 CD34/kg was 2 days
(95% conﬁdence interval, 2-3), for the baseline and
plerixafor-1 groups compared to 2 days (95% conﬁdence
interval, 1-2) for the plerixafor-2 cohort (P < .001 for
comparison of the cumulative incidence plots, log-rank test,
Figure 2A).
The minimum required goal of 2  106 CD34/kg was
achieved in 81%, 95%, and 99% of patients in the baseline,
plerixafor-1, and plerixafor-2 groups, respectively. Thus,
more patients achieved the minimal and optimal CD34
results in the plerixafor-2 group compared to either the
baseline or plerixafor-1 groups (P < .001). Conversely, 19% of
patients in the baseline group failed to mobilize, compared
with 5% and 1% in the plerixafor-1 and plerixafor-2 groups,
respectively (Table 3). The median estimated time to
achieving the goal of 2  106 CD34/kg was 1 day for all the
groups (P < .001 for comparison of the cumulative incidence
plots, log-rank test, Figure 2B).
Examining other parameters of collection success, day 1
apheresis yield (106 CD34 cells/kg, range) was 2.3 (0-26),
2.4 (0.03-28.2), and 3.7 (0.5-29.3), respectively, for the
baseline, plerixafor-1, and plerixafor-2 cohorts (P < .001).
Similarly, the cumulative day-1 and 2 apheresis yield (106
CD34 cells/kg, range) was 4.3 (0-26), 4.4 (0.1-28.2), and 6.5
(0.95-29.3), respectively, for the baseline, plerixafor-1, and
plerixafor-2 cohorts (P < .001). Overall, the number of
patients receiving plerixafor during their ﬁrst mobilization ineach groupwas 0 in the baseline group, 38% in the plerixafor-
1 group, and 58% in the plerixafor-2 group.
In the plerixafor-2 group, 57 of 98 patients (58%) received
plerixafor. Of these 57 patients, 34 and 10 received plerixafor
on the evening of day 4 due to a day-4 PB CD34 number of
<10 and <20, respectively. Ten patients received plerixafor
on day 1, due to day-1 yield <1.5  106 CD34/kg, and 3
received plerixafor after day 1, due to subsequent daily yield
of <0.5  106 CD34/kg.
We also examined the mobilization outcomes based on
the disease types, plasma cell disorders (myeloma and
amyloidosis), or lymphomas (NHL or Hodgkin). Overall, the
Table 4
Cost Analysis
Baseline Plerixafor-1 Plerixafor-2 P Value
Patients 280 219 98
Total cost per patient*
Median $12,500 $12,500 $20,000
Minimum $3,000 $5,000 $5,500
Maximum $146,750 $93,500 $89,750 .01
Mean $17,150 $21,532 $20,617
* Cost analysis includes remobilization costs and has been added to the
original mobilization regardless of when the remobilization occurred.
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optimal number of CD34 cells was higher for the lymphomas
compared with the plasma cell diseases. Among the plasma
cell group, 7% and 14% failed to collect at least 2 and 4million
CD34 cells/kg, respectively, compared with 14% and 29%,
respectively, for the lymphoma group (P < .001 for both
comparisons). We also examined the results with each of the
algorithms within each group. Among the plasma cell group,
21%, 11%, and 5% of patients failed to collect the optimal goal
of 4 million CD34 cells/kg in the baseline, plerixafor-1, and
plerixafor-2 groups, respectively (P < .01). In comparison, in
the lymphoma group, 37%, 26%, and 13% of patients failed to
collect the optimal goal of 4 million CD34 cells/kg in the
baseline, plerixafor-1, and plerixafor-2 groups, respectively
(P < .01). Examining the ability to collect the minimum goal
of 2million CD34 cells/kg,14%, 2%, and 0% of patients failed to
reach the goal in the baseline, plerixafor-1, and plerixafor-2
groups among the plasma cell group, respectively (P < .01).
Similarly, 25%, 9%, and 3% of patients among the lymphoma
group failed to reach the goal in the baseline, plerixafor-1,
and plerixafor-2 groups, respectively (P < .01). Overall, 33%
of the plasma cell group and 47% of the lymphoma group
used plerixafor with the plerixafor-1 algorithm (P ¼ .04)
compared with 53% of the plasma cell group and 69% of the
lymphoma group (P ¼ NS) with the plerixafor-2 algorithm.
Total Mobilization (First and Remobilization) Results
Thirty-nine patients (14%) in the baseline group under-
went at least 1 further attempt at mobilization, compared to
5 in the plerixafor-1 group and only 1 patient in the
plerixafor-2 group. The median days of apheresis including
remobilization attempts were 2 (range, 0-13) in the baseline
cohort, compared to 3 (range,1-12) in the plerixafor-1 group,
and 2 (range 1-9) in the plerixafor-2 group (P¼ .01). The total
days of mobilization and collection were similarly less in the
plerixafor-2 group (median 5 days vs 7 days in the baseline
and the plerixafor-1 groups). The median (106 /kg, range)
CD34 cell dose collected including remobilization attempts
was 5.2 (0-26), 6.2 (0.4-28), and 7.8 (2.5-29), respectively, in
the baseline, plerixafor-1, and plerixafor-2 groups.
Engraftment
Two hundred ten (76%), 188 (87%), and 96 patients (98%),
respectively, from the baseline, plerixafor-1, and plerixafor-2
groups have so far undergone transplantations. The median
times to neutrophil engraftment were 13 days (range,10-50),
14 days (9-28), and 14 days (10-45) for the baseline,
plerixafor-1, and plerixafor-2 groups, respectively. The
median times to platelet engraftment were 13 days (0-57), 13
days (0-83), and 13 days (10-29), for the baseline, plerixafor-
1, and plerixafor-2 groups, respectively. Thus, engraftment
times were similar across all 3 groups.
Cost Analysis
The median total costs of mobilization per patient,
including any remobilization attempt, was $12,500 in the
baseline group, $12,500 in the plerixafor-1 group, and
$20,000 in the plerixafor-2 group (Table 4). Although both
the median and mean costs were higher in the plerixafor-2
group, the range was narrower, and there were fewer
outliers.
DISCUSSION
Adequate PBSC collection is a requirement for ASCT.
Before the FDA approval of plerixafor, approximately 20% ofpatients failed to mobilize adequate numbers of CD34þ cells,
with growth factor alone or in combination with chemo-
therapy. In patients with NHL, the failure rate was higher at
approximately 30% to 35%, with only 29% of patients col-
lecting the optimal dose. In multiple myeloma, the failure
rate was approximately 15%, and only 30% of patients failed
to collect the optimal dose [1]. Numerous studies in the past
have shown various factors that are associated with poor
mobilization, including cumulative amounts and type of
chemotherapy, particularly lenalidomide, alkylating agents,
purine analogs, and platin-containing regimens. Despite
some patients having none of these risk factors, a substantial
number mobilized suboptimal numbers of CD34 cells.
Because plerixafor is administered on day 4 regardless of
whether it is an upfront planned G-CSF þ plerixafor mobili-
zation or, as outlined in our risk-adapted algorithm based on
day-4 CD34 count, pre-existing factors that may increase the
likelihoodof poormobilizationandhence the requirement for
plerixafor, were not analyzed. In addition, the treatment
approaches before mobilization had not changed during the
study period and hence given the sequential nature, we did
not anticipate there being differences between the groups in
terms of premobilization clinical factors.
In our study, the baseline cohort (before the FDA approval
of plerixafor) had a failure rate of 19%, which is similar to that
previously reported by Pusic et al. [1] and by Gertz et al. [2]
Plerixafor in combination with G-CSF is a very effective
mobilization regimen and results in adequate stem cell
collections in the majority of patients [11,12]. However, there
are signiﬁcant cost implications with the administration of
the drug and, as evidenced by the fact that the majority of
patients with multiple myeloma collect optimal stem cell
yields, it may not be necessary in all patients.
We developed this risk-adapted algorithm for patients
who experienced ineffective stem cell mobilization, as
measured by PB CD34 count during mobilization, thereby
targeting the patient population who is at risk of poor or
failed mobilization. These are the patients that usually
require increased apheresis days and potentially higher
posttransplantation resource utilization of transfusions,
antimicrobials, and hospitalizations, if adequate PBSC
mobilization is not achieved. Because of the retrospective
nature of this analysis, additional costs including duration of
hospital stay, transfusions, antimicrobial costs, board and
lodging costs, and posttransplantation complications were
not collected. The goal of this risk-adapted algorithm was to
reduce mobilization failures, increase CD34 mobilization
yields, and limit costs.
PB CD34þ cell counts correlate with the CD34þ apheresis
collection. In a retrospective review of 1,556 patients
undergoing PBSC mobilization at Mayo Clinic, Rochester,
Minnesota, it was demonstrated that a day-4 PB CD34 count
of approximately 10 cells/mL is associated with a higher
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ASCT of 2  106 CD34/kg. In patients with plasma cell
disorders, a day-4 PB CD34 count of >10/mL correlated with
87% of patients achieving a collection of4 106 CD34/kg in
5 or less apheresis. When higher apheresis yields are needed,
it was found that a day-4 PB CD34 count of 21 was the
cutoff required. In patients with a day-4 PB CD34 count of
21, 89% achieved a goal of 8  106 CD34/kg compared with
only 49% whose day-4 PB CD34 count was <21. Among
patients with lymphoma, a day-4 PB CD34 count of 10
correlated to 93% success rate of achieving at least 2  106
CD34/kg compared to only 45% in those patients who had
a PB CD34 count of <10 on day-4. In both the lymphoma and
plasma cell disorder cohorts, day-1 apheresis collection also
predicted total apheresis yield. Day-1 collection of <0.8 in
plasma cell disorders and <1.1  106 CD34/kg in patients
with lymphoma, predicted for failure to obtain a total
apheresis yield of 2  106 CD34/kg [20].
After analysis of plerixafor-1, it became evident that the
day-4 PB CD34 count was most important. The majority of
patients whose PB CD34 count was inadequate (<10) on day
4, subsequently received plerixafor because of either low
CD34 count on day 5 or poor daily yield (<0.5106 CD34/kg)
resulting in the addition of plerixafor [21,22]. Patients who
had a day-1 yield of <1.5 also predictably required plerixafor
due to subsequent poor daily yields. Therefore, in design of
plerixafor-2, the day-5 PB CD34 count was eliminated, the
day-1 yield of <1.5  106 CD34/kg and a higher PB CD34
target for patients collecting for more than 1 transplantation
were added [23]. The hypothesis for the design of plerixafor-
2 was by administering plerixafor earlier to the patients who
required it because of poor yields, may lessen the number of
days of apheresis, days of plerixafor use, and improve the
total apheresis yield.
Our hypothesis for plerixafor-2 was correct, in that the
earlier identiﬁcation of ineffective PBSC mobilization and
initiation of plerixafor (plerixafor-2) improved the results of
PBSC mobilization. This risk-adapted algorithm resulted in
more patients achieving the minimum and optimal yield of
CD34þ cells. The mobilization failure rate was 1%. The use of
the plerixafor-2 algorithm resulted in fewerdays of apheresis,
fewer days of plerixafor, and fewer total days of mobilization
and collection, as compared to the plerixafor-1 algorithm. An
added beneﬁt was of scheduling in the apheresis unit, asmost
patients complete apheresis by the middle of the week and,
therefore, other elective apheresis procedures can be sched-
uled later in the week. Weekend scheduling of stem cell
collections has also been avoided. Patients, as well as clinical
staff, have reported improved satisfaction with a pre-
determined plan, rather than waiting for the PB CD34 count
to reach the cutoff and initiate apheresis. Lower failure rates
also translate to fewerdelays in transplantation. Some studies
have reported a survival beneﬁt for “supermobiliziers,” and it
remains unclear if collecting more stem cells will translate
into improved survival [4,24]. The1-year survival in the phase
III studies with G-CSF þ/ plerixafor showed no difference
between the randomized 2 arms; thus, as of yet, therewas no
survival beneﬁt in the patients treated with plerixafor [25].
Long-term follow-up studies are ongoing, to allow this to be
studied further. Last, because ASCT does not cure all patients,
many will require further chemotherapy posttransplantation
either for relapse or as maintenance in multiple myeloma. It
has been demonstrated that higher CD34þ stem cell yields
used forASCTare associatedwith improvedgraft durability. In
patients with NHL, higher CD34þ stem cell doses wereassociatedwith ahigher percentageof patientswith a platelet
count of 150  109/L at 100 days, 6 months, and 12 months
posttransplantation [24]. Thus, higher CD34þ cell doses at the
time of ASCT may affect the ability to give further chemo-
therapy to treat relapse/progression posttransplantation.
The use of this risk-adapted algorithm of plerixafor-2 was
also associated with increased costs compared to the base-
line and plerixafor-1 cohorts. However, there are a number of
potential unmeasured costs, which were not included in the
cost analysis. This includes both mobilization costs and well
as posttransplantation costs. Posttransplantation costs
including costs of transfusions, antimicrobials, and hospi-
talizationsmay also be increased by slower engraftmentwith
less than optimal CD34 cell yields [3,5-8,26]. Two recent
studies, in fewer patients, looking at cost analysis of “just-in-
time” salvage plerixafor have also shown higher costs asso-
ciated with plerixafor use [27,28].
Chemotherapy mobilization was at the discretion of the
transplantation physician. Although the number of patients
undergoing chemotherapy primed mobilization in each
cohort was small, it is worthwhile to note that with the
introduction of plerixafor, from baseline to plerixafor-1 and
plerixafor-2, the number of patients undergoing chemo-
therapy for mobilization purposes decreased from 10% to 1%
to 2% (P < .001). For patients undergoing chemotherapy-
primed mobilization, the period of cytopenias during mobi-
lization is associated with potential need for transfusions,
antimicrobials, and hospitalizations for complications. The
additional time for the patient and their personal costs, if they
are away from home, also need to be factored in. Had these
been captured in this analysis, it is possible that the costs of
the baseline cohort would have increased because 10% of
these patients had undergone chemotherapy mobilization
compared to only 1% to 2% of plerixafor-1 and plerixafor-2.
Alternatively, in the plerixafor-2 cohort, 58% of patients
required plerixafor for a median of 2 days at a median cost
per patient of $20,000. If plerixafor had been used univer-
sally in all patients for a median of 2 days, the median cost
would have been approximately $34,000 per patient. Thus,
this risk-adapted algorithm allows for selecting the patients
who truly need plerixafor as demonstrated by ineffective
peripheral stem cell mobilization and thereby is a cost saving
compared to universal use. A recent economic analysis by
Kymes et al. [29], from the Washington University trans-
plantation database determined that using G-CSF þ plerix-
afor as upfront mobilization in patients with diffuse large B
cell lymphoma was cost effective. In that analysis, although
the cost of providing plerixafor was higher compared to
G-CSF alone, there was a beneﬁt in quality-adjusted life
years. The expected lifetime cost of providing plerixafor for
patients with diffuse large B cell lymphoma was $25,567
more than with G-CSF alone; however, the beneﬁt was an
accumulated 1.74 more quality-adjusted life years and,
therefore, it was deemed to be cost effective [29]. In our
analysis, we did a cost comparison of the different
approaches in the baseline group, plerixafor-1 algorithm,
and plerixafor-2 algorithm. We did not analyze utility
endpoints.
In conclusion, this study demonstrates that a risk-adapted
algorithm for the use of plerixafor in autologous PBSC
mobilization can be effectively implemented. Although the
earlier identiﬁcation of poor mobilizers and addition of
plerixafor does result in higher per-patient costs over base-
line, it is associated with higher apheresis yields, fewer days
of mobilization and collection, and lower failure rates.
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